CareDx (Nasdaq: NASDAQ:CDNA) shares closed with more than a 5% gain today and are currently trading 2% higher after-hours following the announcement of its acquisition of MediGO. This strategic move aims to expand CareDx's digital health portfolio to cater to the organ procurement organization (OPO) market. Additionally, it will strengthen its pre-transplant offerings, aimed at reducing transplant wait times and increasing access to donated organs.
According to Reg Seeto, CEO of CareDx, by combining their strengths, they plan to enhance operational efficiency, accelerate innovation, and bring more value to the transplant ecosystem, addressing the organ transplant shortage.
Scott Plank, Executive Chairman and Founder of MediGO, also shared his excitement, mentioning that this collaboration would enable them to provide data-driven patient solutions with the integration of MediGO's network, real-time data, and predictive analytics into CareDx's digital health platform.
“We look forward to expanding our current offerings to OPOs, couriers, and hospitals, and scaling the organ transplant system to deliver lifesaving organs and better outcomes for all who need them," added Plank.